Using RWE research to extend clinical trials in diabetes: An example with implications for the future
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: Although randomized, controlled trials (RCTs) are seen as the gold standard for evidence in clinical medicine, a number of considerations are increasing the use of real‐world data (RWD) to generate evidence. A series of methodological challenges must be overcome in order for such real‐world evidence (RWE) to gain acceptance. In diabetes, RWE faces some particular issues that have limited its development. As the natural history of diabetes progresses, patients' disease changes over time and treatments will be modified as a result. This evolving disease and treatment pattern requires application of methods that account for such changes over time. Research developing RWE in diabetes and other conditions has sometimes been subject to important biases, and researchers should be aware of, and take steps to mitigate potential for bias in order to enhance the evidence produced. Results: We review a RWE study that replicated and extended evidence provided by a RCT regarding the effects of weekly exenatide relative to basal insulin (glargine or detemir) to illustrate a potential application of RWE. This study observed a 0.7% decrease in HbA1C for weekly exenatide relative to a 0.5% decrease in HbA1C for the comparator along with a 2 kg weight loss for weekly exenatide relative to a 0.25 kg weight gain, effects that were close to those from the RCT. Further, the RWE study was able to extend results to patient populations that were not well represented in the RCT. Conclusion: Despite numerous challenges, RWE can be used to complement evidence from RCTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646 · cited 1×
“The cohorts were formed using a new-user cohort design to emulate a RCT (Figure 3).(23,24) This approach begins follow-up for study outcomes at the point of treatment initiation for both once-weekly exenatide and basal insulin cohorts, as would a RCT.”
Method
Cited by
Caruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2022) · Metabolites · doi:10.3390/metabo12020183 · Cited by 86
“However, the strict requirements of randomized controlled trials come at the expense of generalizability, as their results are reliably informative only for populations with the same features and in a similar setting of care [2].”
BackgroundYang, C.-Y., Chen, Y.-R., Ou, H.-T., & Kuo, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01211-4 · Cited by 51
“Our real-world evidence of the comparative effectiveness of GLP-1RAs versus insulin complements existing trial evidence by translating the efficacy of GLP-1RAs in clinical trials to its effectiveness in clinical practice among a broader spectrum of real-world patient populations for supporting the rational selection o…”
MethodChang, K.-C., Shao, S.-C., Kuo, S., Yang, C.-Y., Chen, H.-Y., Chan, Y.-Y., & Ou, H.-T. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01148-8 · Cited by 28
Alsheikh, A., Alshehri, A., Alzahrani, S., Jammah, A. A., Alqahtani, F., Alotaibi, M., Aldahash, R., Alhozali, A. M., Alsabaan, F., Almehthel, M., et al. (2024) · Diabetes Therapy · doi:10.1007/s13300-023-01516-z · Cited by 16
Metadata
- Authors
- Seeger, J. D., Nunes, A., & Loughlin, A. M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2020-04
- Volume
- 22
- Issue
- S3
- Pages
- 35-44
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W3014125475
- Cited by
- 20
- References
- 1
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.